| Nov 7 |
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
|
| Nov 7 |
Aurinia Pharma GAAP EPS of $0.10 beats by $0.09, revenue of $67.77M beats by $10.08M
|
| Nov 7 |
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
|
| Nov 6 |
Aurinia Pharma Q3 2024 Earnings Preview
|
| Nov 2 |
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago
|
| Oct 30 |
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
|
| Oct 11 |
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
|
| Sep 27 |
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Could Be Less Than A Year Away From Profitability
|
| Sep 24 |
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
|
| Sep 19 |
Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment
|
